PATENT CLAIM ANALYSIS

Application Number: 16213550
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "265100"]

Abstract:
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Claim (Index 16):
The method of  claim 1 , wherein the dose of ruxolitinib, or a pharmaceutically acceptable salt thereof, is about 10 mg/day to about 50 mg/day.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 98.0
- Lexical Diversity: 1.45652
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15373923', '14811038', '15815255', '14155212', '15166380']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8014792420727141
- 35 USC 102 Novelty (BERT): 0.5647417709328962
- Combined Prediction Score: 0.7778054949587324
- Mean Citation Score: 428.94012
- Max Citation Score: 460.80817
- Similarity Product: 319.67395081081327

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test